Holen Sie sich die Stockscreener-App
0.5396
4.27%
0.0221
Handel nachbörslich:
.53
-0.0096
-1.78%
Schlusskurs vom Vortag:
$0.5175
Offen:
$0.52
24-Stunden-Volumen:
6.09M
Relative Volume:
1.10
Marktkapitalisierung:
$125.82M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.7195
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
+1.83%
1M Leistung:
+9.67%
6M Leistung:
-53.88%
1J Leistung:
-44.66%
1-Tages-Spanne:
$0.5111
$0.56
1-Wochen-Bereich:
$0.42
$0.56
52-Wochen-Spanne:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5396 | 127.00M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
Sangamo Therapeutics (SGMO.O) Surges 11.3% on Strong KDJ Signal Amid Mixed Biotech Sector Moves - AInvest
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Transcript : Sangamo Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sangamo: Q2 Earnings Snapshot - Greenwich Time
Earnings call transcript: Sangamo Therapeutics Q2 2025 earnings miss, stock drops - Investing.com Australia
Sangamo Q2 2025 slides: Neurology pipeline advances amid financial challenges - Investing.com Australia
Sangamo Therapeutics shares fall 4.55% premarket after Q2 revenue misses estimates. - AInvest
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics 2025 Q2 Earnings Improved Losses Despite Revenue Surge - AInvest
Sangamo Therapeutics Reports Strong Q2 2025 Results - TipRanks
Sangamo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Sangamo Therapeutics Q2 Misses Revenue Estimates and Reiterates 2025 Guidance — What This Means for Its Strategic Path Forward - AInvest
Sangamo Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Sangamo Therapeutics Q2 revenue misses estimates - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - Yahoo Finance
Sangamo Therapeutics Announces Second Quarter 2025 Earnings CallLife Science Industry News - Zenopa
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedHigh-yield market plays - Jammu Links News
What are Sangamo Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
How does Sangamo Therapeutics Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
Why is Sangamo Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on top-performing stocks - Jammu Links News
What institutional investors are buying Sangamo Therapeutics Inc. stockRapid growth trajectories - Jammu Links News
Does Sangamo Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent investment plans - Jammu Links News
Is Sangamo Therapeutics Inc. a good long term investmentBuild a portfolio with strong long-term growth - Jammu Links News
What makes Sangamo Therapeutics Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
When is Sangamo Therapeutics Inc. stock expected to show significant growthAccess powerful market insights for free - Jammu Links News
What drives Sangamo Therapeutics Inc. stock priceInvest smarter with expert stock picks - Jammu Links News
What are the technical indicators suggesting about Sangamo Therapeutics Inc.Free Stock Index Interpretation - Jammu Links News
Sangamo Therapeutics Announces Q2 2025 Earnings Call and Webcast - AInvest
How strong is Sangamo Therapeutics Inc. company’s balance sheetDaily Trading Strategy For Smart Trading - Jammu Links News
Genomic Medicine Leader Sangamo Sets Q2 Earnings Call: Key Financial Updates Coming August 7 - Stock Titan
Has Sangamo Therapeutics Inc. formed a bullish divergenceOversold Bounce Stock Play Ideas Gain Attention - metal.it
Published on: 2025-07-30 16:12:38 - beatles.ru
Will Sangamo Therapeutics Inc. outperform the marketAI Trading Suggestions With Accuracy Focus Released - metal.it
Hunter Syndrome Treatment Market Exclusive Report with - openPR.com
How volatile is Sangamo Therapeutics Inc. stock compared to the marketAI Powered Updates From AI Tools - Jammu Links News
What is the dividend policy of Sangamo Therapeutics Inc. stockDiscover high-impact stocks for growth - Jammu Links News
What are the latest earnings results for Sangamo Therapeutics Inc.Free Stock Updates For 2025 - jammulinksnews.com
Published on: 2025-07-28 06:51:50 - Jammu Links News
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSafe and Scalable Investment Tips - metal.it
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):